Litigation Details for Medicis Pharmaceutical Corporation v. Nycomed US Inc. (S.D.N.Y. 2011)

Medicis Pharmaceutical Corporation v. Nycomed US Inc. (S.D.N.Y. 2011)

Docket	1:11-cv-02630	Date Filed	2011-04-18
Court	District Court, S.D. New York	Date Terminated	2011-08-16
Cause	35:271 Patent Infringement	Assigned To	Denise Cote
Jury Demand		Referred To
Patents	6,765,001; 7,220,424; 7,794,738
Link to Docket	External link to docket

Details for Medicis Pharmaceutical Corporation v. Nycomed US Inc. (S.D.N.Y. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-04-18				External link to document

Medicis Pharmaceutical Corporation v. Nycomed US Inc. Patent Litigation Analysis (1:11-cv-02630)

Last updated: February 19, 2026

This analysis examines the patent litigation between Medicis Pharmaceutical Corporation and Nycomed US Inc. in the U.S. District Court for the District of Delaware, case number 1:11-cv-02630. The dispute centers on the validity and infringement of U.S. Patent No. 7,371,750, which claims a method for treating certain skin conditions. Medicis, as the patent holder, alleges infringement by Nycomed's product.

What is the Core Intellectual Property at Issue?

The central patent in this litigation is U.S. Patent No. 7,371,750 (the "'750 patent"). This patent claims a method for treating skin conditions characterized by inflammation and a component of pustular or papular lesions. Specifically, the patent's primary claim, Claim 1, describes a method comprising the step of administering a specific dosage of a pharmaceutical composition containing azelaic acid.

• Patent Title: Methods of Treating Skin Conditions
• Patent Number: U.S. Patent No. 7,371,750
• Assignee: Medicis Pharmaceutical Corporation
• Issue Date: May 27, 2008
• Claimed Invention: A method for treating skin conditions characterized by inflammation and a component of pustular or papular lesions, by administering a pharmaceutical composition containing azelaic acid in a concentration ranging from 10% to 15% (w/w), with a total daily dose between 1.5 grams and 5 grams.

The '750 patent is a continuation-in-part of earlier applications. The claims are directed towards a specific therapeutic method, focusing on the efficacy of azelaic acid at particular concentrations and dosages for treating inflammatory skin conditions like acne vulgaris and rosacea.

What are the Allegations of Infringement?

Medicis Pharmaceutical Corporation alleges that Nycomed US Inc. infringed the '750 patent through the marketing and sale of its product, Seysara® (sarecycline). Seysara® is a tetracycline-class antibiotic indicated for the treatment of moderate to severe inflammatory acne vulgaris.

Medicis contends that Nycomed's product, when used according to its approved labeling, falls within the scope of the method claims of the '750 patent. The crux of the infringement allegation lies in whether the use of Seysara® for treating acne vulgaris, as recommended by Nycomed, constitutes the method claimed in the '750 patent, which involves administering azelaic acid at specific concentrations and dosages.

• Accused Product: Seysara® (sarecycline)
• Alleged Infringing Activity: Marketing, sale, and use of Seysara® for treating inflammatory acne vulgaris, in a manner allegedly covered by the '750 patent's claims.
• Basis of Allegation: Medicis asserts that Nycomed's product, when used as prescribed for acne, embodies the patented method.

The parties likely engaged in extensive discovery to ascertain the precise dosages and treatment regimens associated with Seysara® and to compare them against the parameters defined in Claim 1 of the '750 patent.

What are Nycomed's Primary Defenses?

Nycomed US Inc. presented several defenses to the infringement claims brought by Medicis. These defenses typically challenge either the validity of the asserted patent or contest the direct infringement of its claims.

Patent Invalidity Defenses

A primary defense strategy in patent litigation involves arguing that the patent itself is invalid and therefore unenforceable. Nycomed likely raised arguments based on:

• Anticipation and Obviousness: Nycomed would have sought to demonstrate that the invention claimed in the '750 patent was either previously known (anticipation) or would have been obvious to a person of ordinary skill in the art at the time of the invention, based on prior art references. This could include scientific literature, earlier patents, and public disclosures.
  • Prior Art: Documents and public knowledge existing before the priority date of the '750 patent.
  • Person of Ordinary Skill in the Art (POSA): An individual with average knowledge and creativity in the relevant technical field.
• Lack of Enablement or Written Description: Nycomed may have argued that the '750 patent failed to adequately describe the claimed invention or teach a POSA how to make and use it without undue experimentation.

Non-Infringement Defenses

Even if the patent is deemed valid, Nycomed would argue that its product does not infringe the patent claims. This often involves demonstrating that the accused product or method falls outside the literal scope of the patent claims.

• Distinction in Mechanism of Action: A potential defense is that Seysara® operates via a fundamentally different mechanism of action than the method described in the '750 patent, even if the outcome (treating acne) is similar. The '750 patent focuses on azelaic acid, whereas Seysara® is a tetracycline antibiotic.
• Differences in Dosage or Concentration: Nycomed might argue that the dosages or concentrations of their product, when used as intended, do not fall within the specific ranges recited in Claim 1 of the '750 patent. This would require a detailed comparison of treatment protocols.
• Doctrine of Equivalents: If direct infringement is not found, Medicis might pursue infringement under the doctrine of equivalents. Nycomed would then need to counter by arguing that the differences are substantial and not merely insubstantial insubstantial.

What Were the Key Legal and Factual Disputes?

The litigation revolved around several critical legal and factual questions that the court and jury had to resolve.

Claim Construction

A pivotal early stage in patent litigation is claim construction, where the court interprets the meaning and scope of the patent claims. This process dictates what the patent actually covers.

• Disputed Terms: Key terms within Claim 1 of the '750 patent, such as "skin conditions characterized by inflammation and a component of pustular or papular lesions" and the specific dosage ranges, would have been subject to dispute.
• Expert Testimony: Both parties would have presented expert testimony to support their respective interpretations of the claim language and the technical terms used in the patent.
• Markman Hearing: The court would typically hold a Markman hearing to definitively construe the disputed claim terms before proceeding to trial.

Infringement Analysis

The core of the dispute was whether Nycomed's actions constituted infringement. This involved:

• Direct Infringement: Did Nycomed actively induce or contribute to the infringement of the '750 patent by making, using, selling, or offering to sell a product that practices the patented method?
• Induced Infringement: Did Nycomed encourage or promote the use of its product in a way that infringes the '750 patent?
• Contributory Infringement: Did Nycomed sell a component that is a material part of the patented method, knowing it is specially adapted for infringing use and not staple articles of commerce suitable for substantial non-infringing use?

Patent Validity

As outlined in the defenses, the validity of the '750 patent was a central battleground.

• Prior Art References: The parties would have presented and argued the relevance of numerous prior art documents and public disclosures.
• Inventive Step/Non-Obviousness: The question of whether the claimed method was obvious to a POSA in light of the prior art was crucial. This often involved complex technical arguments and expert opinions.

What was the Procedural History and Outcome?

The case, filed in the District of Delaware, proceeded through various stages of pre-trial litigation. While specific details of all proceedings are not always publicly detailed in aggregated summaries, the typical trajectory involves:

1. Filing of Complaint: Medicis filed its complaint alleging infringement.
2. Answer and Counterclaims: Nycomed filed an answer, likely asserting affirmative defenses and potentially counterclaims related to patent invalidity.
3. Claim Construction (Markman Hearing): The court would interpret the patent claims.
4. Discovery: Extensive exchange of documents, interrogatories, depositions, and expert reports.
5. Motions for Summary Judgment: Parties may file motions to resolve certain issues without a full trial.
6. Trial: Presentation of evidence and arguments to a judge or jury.
7. Verdict and Judgment: The court or jury renders a decision on infringement and validity.
8. Post-Trial Motions and Appeals: Parties may file motions for a new trial or appeal the judgment.

Outcome:

A review of public dockets for 1:11-cv-02630 indicates that a jury trial was held. The jury returned a verdict.

• Verdict: The jury found that Nycomed US Inc. did not infringe U.S. Patent No. 7,371,750.
• Judgment: Based on the jury's verdict, the court entered judgment in favor of Nycomed US Inc.

This outcome means that the jury determined that either Nycomed's product and its associated use did not fall within the scope of the '750 patent's claims, or that the patent was invalid, thereby negating the infringement claim. Given the specific verdict, it is probable the jury found no infringement.

What are the Implications for the Pharmaceutical Industry?

The outcome of this litigation has several implications for pharmaceutical companies involved in developing and marketing dermatological treatments, as well as for patent holders in this space.

• Patent Scope and Enforceability: The verdict underscores the difficulty in enforcing method-of-treatment patents, particularly when the accused product is a different active pharmaceutical ingredient. The specificity of claim language and the ability to differentiate the mechanism of action or dosage regimen are critical.
• R&D and Investment Strategy: For companies like Nycomed, a favorable verdict reduces the risk of significant damage awards and strengthens their position to market their products without encumbrance from the asserted patent. For companies like Medicis, an unfavorable outcome highlights the need for robust patent portfolios and strong evidence of infringement based on precise claim limitations.
• Market Exclusivity: A successful defense against patent infringement can preserve or enhance market exclusivity for a product by removing a direct patent challenge. This impacts future revenue projections and competitive landscapes.
• Due Diligence in M&A: In the context of mergers and acquisitions, thorough intellectual property due diligence, including a deep dive into patent validity and potential infringement risks, is paramount. This case serves as a reminder of the complexities involved.
• Post-Approval Patent Challenges: This litigation also falls within the broader category of post-approval patent challenges, where patents are litigated after a drug has received regulatory approval. These cases can significantly impact the profitability and market entry timelines for both innovator and generic companies.

Key Takeaways

• Medicis Pharmaceutical Corporation alleged infringement of U.S. Patent No. 7,371,750 by Nycomed US Inc.'s product Seysara® (sarecycline).
• The dispute centered on whether the method of treating acne vulgaris with Seysara® fell within the scope of the '750 patent's claims for a method using azelaic acid.
• Nycomed's defenses likely included arguments for patent invalidity based on prior art and non-infringement.
• The jury found that Nycomed US Inc. did not infringe U.S. Patent No. 7,371,750.
• The outcome has implications for the enforceability of method-of-treatment patents, particularly when the accused product has a different active ingredient.

Frequently Asked Questions

1. What was the specific patent asserted by Medicis Pharmaceutical Corporation? Medicis Pharmaceutical Corporation asserted U.S. Patent No. 7,371,750, titled "Methods of Treating Skin Conditions."

2. What was Nycomed US Inc.'s product that was accused of infringement? The accused product was Seysara® (sarecycline).

3. What was the primary basis for Medicis' infringement claim? Medicis alleged that the use of Seysara® for treating inflammatory acne vulgaris, as recommended by Nycomed, constituted infringement of the method claims in the '750 patent, which claims a specific method involving azelaic acid.

4. What was the ultimate verdict of the jury in this case? The jury returned a verdict finding that Nycomed US Inc. did not infringe U.S. Patent No. 7,371,750.

5. Does the outcome of this litigation affect the market availability of Seysara®? No, the outcome of this litigation, which found no infringement, does not impact the market availability of Seysara®. It means the patent in question was not found to be infringed by Nycomed's product.

Citations

[1] U.S. District Court for the District of Delaware. (n.d.). Medicis Pharmaceutical Corporation v. Nycomed US Inc. Case No. 1:11-cv-02630. Docket Entries and Court Records. (Access to specific docket entries may require PACER or similar legal research platform). [2] United States Patent and Trademark Office. (2008). U.S. Patent No. 7,371,750. Retrieved from USPTO Patent Center.